Michael Gordon

Michael S. Gordon, D.P.A

Michael S. Gordon, D.P.A
Michael S. Gordon, D.P.A
Senior Research Scientist

D.P.A., Public Administration, University of Baltimore
mgordon@friendsresearch.org
Phone: 410-837-3977 ext. 251
Fax: 410-752-4218
Brief Biography

Dr. Gordon has expertise and experience in developing, implementing, and evaluating innovative substance abuse treatment interventions for criminal justice populations (prisoners, parolees, probationers) with histories of opioid addiction. In addition, he conducts HIV and technology-based research with criminal justice populations. Dr. Gordon has been Principal Investigator or Co-Investigator on six major studies that have contributed to the field of substance abuse, HIV and criminal justice: (1) methadone maintenance for prisoners, (2) buprenorphine for prisoners, (3) long-acting naltrexone for prisoners, (4) long-acting naltrexone for probationers and parolees; (5) rapid HIV testing for criminal justice populations, and 6) criminal justice drug abuse treatment studies.

Dr. Gordon is a two-time recipient of the National Institutes of Health (NIH) Clinical Research Loan Repayment Program Award. Furthermore, he has been the recipient of three travel awards, two from the National Institute on Drug Abuse (NIDA), and one from the College on Problems of Drug Dependence (CPDD). Dr. Gordon also received the Friends Research Institute 2008 Daniel Mendelsohn/ New Investigator Award. In addition to his work at FRI, since 2011, Dr. Gordon has served as an Adjunct Professor in the School of Humanities and Social Sciences at Stevenson University.

Selected Publications
Crable E, Blue T, Mackenzie M, Rich J, Gordon MS (in press). Effect of case management on HIV outcomes for community corrections population: Results of an 18-month randomized controlled trial.. Journal of Acquired Immune Deficiency Syndrome.
Schwartz RP, Mitchell MM, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Gordon MS, Jaffe JH (in press). Pharmacotherapy for Opioid Addiction in Community Corrections. International Review of Psychiatry. 2018 Dec 6:1-19. doi: 10.1080/09540261.2018.1524373. [Epub ahead of print] PMID: 30522370
Belcher, A. M., Smith, H., Welsh, C., Fitzsimons, H., Dalverny, A., Lasher, D., Coble, K., Greenblatt, A. D., Blue, T., Gordon, M., & Weintraub, E. (2025). Bridging the gap: Post-release outcome evaluation of the first jail-based telemedicine buprenorphine program.. Drug and alcohol dependence, 277,. 112950. Advance online publication. https://doi.org/10.1016/j.drugalcdep.2025.112950
Blue, T. R., Gordon, M. S., Vocci, F. J., Fishman, M. J., Gwin Mitchell, S., & Wenzel, K. (2025). A Naturalistic Study of Individuals Involved in the Justice System Who Experienced Both Formulations of Extended-release Buprenorphine.. Journal of addiction medicine,. 10.1097/ADM.0000000000001430. Advance online publication. https://doi.org/10.1097/ADM.0000000000001430
Cullins, Z., Ross, A., Beckwith, C. G., Gordon, M., Blue, T., Black, C., Camp, H., & Brinkley-Rubinstein, L. (2025). Staff perspectives on using long-acting antiretroviral treatment among persons being released from carceral settings in Baltimore, Maryland, USA. AIDS care. 1–7. Advance online publication.
Rostam-Abadi, Y., Liebschutz, J. M., Subramaniam, G., Stone, R., Appleton, N., Mazel, S., Alexander, K., Brill, S. B., Case, A., Gelberg, L., Gordon, A. J., Hong, H., Incze, M. A., Kawasaki, S. S., Kim, T., Kline, M., Lovejoy, T. I., McCormack, J., Zhang, S., & McNeely, J. (2025). Understanding the characteristics and comorbidities of primary care patients with risky opioid use: Baseline data from the multi-site “Subthreshold Opioid Use Disorder Prevention” (STOP) Trial.. Journal of general internal medicine,. 10.1007/s11606-025-09613-4. Advance online publication. https://doi.org/10.1007/s11606-025-09613-4
Sawyer-Morris, G., Halverson, M., Maher, K. M., Carswell, S. B., & Gordon, M. S. (2025). Implementing real-time assessments of substance use cravings, triggers, and mood: a feasibility study with justice-involved populations. Health & Justice. 13(1), 60
Smith, L. R., Faragó, F., Blue, T., Witte, J. C., Gordon, M. S., & Taxman, F. S. (2025). Are Operations Backed by Best Practices in American Problem-Solving Courts?.. Journal of substance use, 30. (5), 767–773. https://doi.org/10.1080/14659891.2024.2403080
Gordon, M.S., Blue, T., Vocci, F., Mitchell, S., Wenzel, K., & Fishman, M. (2024). Buprenorphine dose induction in opioid non-tolerant individuals in jail.. Drug and Alcohol Dependence Reports, 12 (September),100261.
Smith, L. R., Faragó, F., Blue, T., Witte, J. C., Gordon, M. S., & Taxman, F. S. (2024). Are operations backed by best practices in American problem-solving courts?. Journal of Substance Use,. 1–7. https://doi.org/10.1080/14659891.2024.2403080
Blue, T. R., Fletcher, J. B., Monico, L. B., Gordon, M. S., Schwartz, R. P., & Mitchell, S. G. (2023). Jail and treatment staff attitudes regarding MOUDs before and after an implementation intervention.. Journal of Offender Rehabilitation, 62. (7), 411-426. https://doi.org/10.1080/10509674.2023.2246446
Carswell, S.B., Gordon, M.S., Gryczynski, J., Horodyski, A.M., Ferguson, K.N., Maher, K.M., & Vocci, F.J. (2023). The daily progress system – a recovery support tool to improve engagement and retention in outpatient substance use treatment.. Journal of Substance Use,. 1-6.DOI: 10.1080/14659891.2023.2261036
Farago F, Smith L, Cloud V, Gordon M, & Taxman F (2023). Pilot study: An exploration of Medication Assisted-Treatment (MAT) for indigenous Americans within tribal healing to wellness courts.. Journal of Qualitive Criminal Justice.. https://doi.org/10.21428/88de04a1.d21bf9fc
Smith, L. R., Faragó, F., Blue, T., Witte, J. C., Gordon, M. S., & Taxman, F. S. (2023). Viewing Then Doing?: Problem-Solving Court Coordinators’ Perceptions of Medications for Opioid Use Disorders from a Nationally Representative Survey in the United States.. Subst Use Misuse, 58. (13), 1780-1788. https://doi.org/10.1080/10826084.2023.2247076
Carswell, S.B., Gordon MS, Gryczynski J, Taxman FS, Schadegg M, Ferguson KN & Maher K (2022). Continuing care application for probationers and parolees with substance use disorders.. Journal of Drug Education, 51. (1-2), 32-48, DOI 10.1177/00472379221111.
Ludwig, A., Monico, L. B., Blue, T., Gordon, M. S., Schwartz, R. P., & Mitchell, S. G. (2022). Development and use of a checklist for the implementation of medication for opioid use disorder in jails.. Implementation Research and Practice, 3. , 26334895221101214. Doi: 10.1177/26334895221101214
Crable, E. L., Blue, T. R., McKenzie, M., Rich, J. D., & Gordon, M. S. (2021). Effect of case management on HIV outcomes for community corrections population: Results of an 18-month randomized controlled trial.. JAIDS Journal of Acquired Immune Deficiency Syndromes, 87. (1), 755-762.
Gordon, M. S., Mitchell, S. G., Blue, T. R., Vocci, F. J., Fishman, M. J., Murphy, S. M., Couvillion, K., Maher, K., Ryan, D., Wenzel, K., Danner, M. L., & Jarvis, D. K. (2021). A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.. Journal of Substance Abuse Treatment, 128,. 108241. https://doi.org/10.1016/j.jsat.2020.108241
Gordon MS, Mitchell SG, Blue TR, Vocci FJ, Fishman MJ, Murphy SM, CouvillionK, Maher K, Ryan D, Wenzel K, Danner ML, Jarvis DK (2020). A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.. Journal of Substance Abuse Treatment. 108241.
Murphy SM, Jeng PJ, Poole SA, Jalali A, Vocci FJ, Gordon MS, Woody GE, Polsky D (2020). Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.. Addiction Science & Clinical Practice. 15, 1-11
Blue TR, Gordon MS, Schwartz RP, Couvillion K, Vocci FJ, Fitzgerald TT, O’Grady KE (2019). Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine. Addiction Science & Clinical Practice. 14(1):45. doi: 10.1186/s13722-019-0172-2. PMID:31787108
Gordon MS, Vocci FJ, Taxman F, Fishman M, Sharma B, Blue TR, O’Grady KE (2019). A Randomized Controlled Trial of Buprenorphine for Probationers and Parolees: Bridging the Gap into Treatment. Contemporary Clinical Trials. 79:21-27. doi: 10.1016/j.cct.2019.02.009. Epub 2019 Feb 20. PMID: 30797042
Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA (2019). Approaches for Creating Comparable Measures of Alcohol use Symptoms: Harmonization with Eight Studies of Criminal Justice populations. Drug and Alcohol Dependence. 194:59-68. doi: 10.1016/j.drugalcdep.2018.10.003. Epub 2018 Oct 23. PMID: 30412898
Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D (2019). Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. Journal of Substance Abuse Treatment. 103:1-8. doi: 10.1016/j.jsat.2019.05.002. Epub 2019 May 9. PMID: 31229187
Soares WE, Wilson D, Gordon MS, Lee JD, Nunes EV, O’Brien, CP, Shroff M, Friedmann PD (2019). Incidence of Future Arrests in Adults involved in the Criminal Justice System with Opioid Use Disorder receiving Extended Release Naltrexone compared to Treatment as Usual. Drug and Alcohol Dependence. 194, 482-486 doi: 10.1016/j.drugalcdep.2018.10.035. Epub 2018 Dec 3. PMID:30522048
Carswell, S.B., Gordon MS, Gryczynski J, and Tangires S (2018). The daily progress system: A proof of concept pilot study of a recovery support technology tool for outpatient substance abuse treatment. The American Journal of Drug and Alcohol Abuse. Published online: 30 May 2018
Chen DT, Ko TM, Allen AA, Bonnie RJ, Suratt CE, Appelbaum PS, Nunes EV, Friedmann PD, Lee JD, Gordon MS, McDonald R, Wilson D, Boney TY, Murphy SM, and O’Brien CP (2018). Personal control over decisions to participate in research by persons with histories of both substance use disorders and criminal justice supervision. Journal of Empirical Research on Human Research Ethics. 13(2):160-172. doi: 10.1177/1556264618755243. Epub 2018 Feb 20.PMID: 29460668
Friedmann PD, Wilson D, Nunes EV, Hoskinson Jr R, Lee JD, Gordon MS, Murphy SM, Bonnie RJ, Chen DT, Boney TY, O’Brien CP (2018). Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?. Journal of Substance Abuse Treatment. Available at: http://dx.doi.org/10.1016/j.jsat.2017.01.018
Gordon MS, Blue TR, Couvillion K, Schwartz RP, O’Grady KE, Fitzgerald TT, Vocci FJ (2018). Initiating buprenorphine treatment prior to versus after release from prison: Arrest outcomes. Drug and Alcohol Dependence. 188:232-238. doi: 10.1016/j.drugalcdep.2018.04.010. Epub 2018 May 12. PMID: 29783095
Gordon MS, Crable EL, Carswell, S.B., Leopold J, Hodo-Powell J, McKenzie M, and Rich JD (2018). A randomized controlled trial of intensive case management (Project Bridge) for HIV-infected probationers and parolees. AIDS and Behavior. 22(3):1030-1038. doi: 10.1007/s10461-017-2016-y. PMID: 29273946
Nunes EV, Gordon MS, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hi MC, Boney TB, Wilson D, O’Brien CP (2018). Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. . Journal of Substance Abuse Treatment. Available at: http://dx.doi.org/10.1016/j.jsat.2017.04.016
Schwartz RP, Mitchell MM, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Gordon MS, Jaffe JH (2018). Pharmacotherapy for opioid addiction in community corrections. International Review of Psychiatry. 30(5):117-135. doi: 10.1080/09540261.2018.1524373. Epub 2018 Dec 6. PMID: 30522370
Soares W, Wilson D, Rathlev N, Lee J, Gordon MS, Nunes E, O’Brien CP, Friedmann P (2018). Healthcare Utilization in Adults with Opioid Dependence receiving Extended Release Naltrexone compared to Treatment as Usual. Journal of Substance Abuse Treatment. Available at: http://dx.doi.org /10.1016/j.jsat.2017.05.009
Allen A, Chen D, Bonnie RJ, Koa TM, Surratt CE, Lee JD, Friedmann P, Gordon MS, McDonald R, Murphy S, Boney T, Nunes E, O’Brien CP (2017). Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. Journal of Substance Abuse Treatment. 81, 66–72
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM (2017). Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, and Policy. 12(1):24. doi: 10.1186/s13011-017-0107-4. PMID:28511680
Gordon MS (2017). Television interview with Investigative Reporter Barry Sims of WBAL-TV Channel 11. Long-acting naltrexone for prisoners.
Gordon MS, Carswell, S.B., Peters EN, Tangires S, Kinlock TW, Vocci FJ, and Restivo L (2017). Avatar assisted therapy: A novel technology-based Intervention to treat substance use disorders. In Pam Lassiter (ed.), Annual Review of Addictions and Offender Counseling: Best Practices III. (p 97 - 114). Eugene, OR: Wipf & Stock Publishers.
Gordon MS, Carswell, S.B., Schadegg M, Mangen K, Merkel K, Tangires S, Vocci FJ (2017). Avatar-assisted therapy: a proof-of-concept pilot study of a novel technology-based intervention to treat substance use disorders. American Journal of Drug and Alcohol Abuse. 43(5):518-524. doi: 10.1080/00952990.2017.1280816.
Gordon MS, Fitzgerald TT (2017). Television interview with Maryland Department of Public Safety Reporter Gerard Shields. Long-acting naltrexone for prisoners.
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE, Fitzgerald TT, Vocci FJ (2017). A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release. Drug and Alcohol Dependence. 172:34-42. doi: 10.1016/j.drugalcdep.2016.11.037. Epub 2017 Jan 11. PMID: 28107680
Gordon MS, Vocci FJ, Fitzgerald TT, O’Grady KE, O’Brien CP (2017). Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment. Contemporary Clinical Trials. 53:130-136. doi: 10.1016/j.cct.2016.12.015. PMID:28011389
Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA (2017). Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium. AIDS and Behavior. doi. 10.1007/s10461-017-1722-9. PMID:28188460
Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM (2017). Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care. 29(4):464-468. doi: 10.1080/09540121.2016.1263721
Zaller N, Gordon MS, Bazerman L, Kuo I, Beckwith C (2017). Individuals under community supervision in Baltimore, MD. Journal of Correctional Healthcare. 23(3), 305-312
Gordon MS, Carswell, S.B., Wilson M, Kinlock TW, Restivo LL, McKenzie M, Rich JD, (2016). Factors Associated With Receiving Rapid HIV Testing Among Individuals on Probation or Parole. Journal of Correctional Health Care. 22(4):290-299. PMID: 27742854
Kinlock TW, and Gordon MS (2016). Heroin and Other Opiates. In Henry H. Brownstein (ed.). The Handbook of Drugs and Society. (pp. 72-89). West Sussex, UK: John Wiley & Sons, Inc.
Mitchell SG, Willett J, Monico LB, James A, Rudes DS, Viglioni J, Schwartz RP, Gordon MS, Friedmann PD (2016). Community Correctional Agents’ Views of Medication-Assisted Treatment: Examining their Influence on Treatment Referrals and Community Supervision Practices.. Substance Abuse. 37(1):127-33. doi: 10.1080/08897077.2015.1129389. PMID: 26860334. PMCID: PMC4823810.
Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, Sudec LJ, O’Grady KE, Vocci FJ, Shabazz H (2015). Buprenorphine Treatment for Probationers and Parolees. Substance Abuse. 36(2):217-25. doi: 10.1080/08897077.2014.902787. Epub 2014 Apr 4. PMID: 24701967
Gordon MS, Kinlock TW, Vocci FJ, Fitzgerald TT, Memisoglu A, Silverman B (2015). A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners. Journal of Substance Abuse Treatment. 59:52-8. doi: 10.1016/j.jsat.2015.07.005. Epub 2015 Jul 18. PMID: 26299956
Kinlock TW and Gordon MS (2015). Pharmacotherapy for Incarcerated Individuals with Histories of Heroin Addiction. In Ayman M. Fareed (ed.),. Heroin Addiction: Prevalence, Treatment Approaches and Health Consequences. (pp. 127-142). Hauppauge, NY: Nova Science Publishers, Inc.
Lee JD, Friedmann PD, Boney TY, Hoskinson RA Jr, McDonald R, Gordon MS, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O’Brien CP (2015). Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemporary Clinical Trials. 41:110-7
Vocci FJ, Schwartz RP, Wilson ME, Gordon MS, Kinlock TW, Fitzgerald TT, O’Grady KE, Jaffe JH (2015). Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.. Drug and Alcohol Dependence. 156:133-8. doi: 10.1016/j.drugalcdep.2015.09.001. Epub 2015 Sep 7. PMID: 26409751.
Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ (2014). A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug and Alcohol Dependence. 142, 33-40. doi: 10.1016/j.drugalcdep.2014.05.011. Epub 2014 Jun 2. PMID: 24962326
Friedmann PD, Ducharme LJ, Welsh W, Frisman L, Knight K, Kinlock T, Mitchell SG, Hall E, Urbine T, Gordon MS, Abdel-Salam S, O’Connell D, Albizu-Garcia C, Knudsen H, Duval J, Fenster J; Jennifer Pankow for the CJ-DATS MATICCE Workgroup (2013). A cluster randomized trial of an organizational linkage intervention for offenders with substance use disorders: study protocol. Health Justice. 19; 1(6). doi: 10.1186/2194-7899-1-6. PMID: 25309847. PMCID: PMC4193542
Gordon MS, Kinlock TW, Couvillion KA, Schwartz RP, Wilson ME, O’Grady KE (2013). Gender differences among prisoners with pre-incarceration heroin dependence participating in a randomized clinical trial of buprenorphine treatment.. Journal of Offender Rehabilitation. 52(5), 376-391.
Gordon MS, Kinlock TW, McKenzie M, Rich JD, Wilson ME (2013). Rapid HIV testing for individuals on probation/parole: Outcomes of an intervention trial.. AIDS and Behavior. 17(6), 2022-2030.
Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, O’Grady KE (2013). The Severity, Frequency, and Variety of Crime in Heroin-Dependent Prisoners Enrolled in a Buprenorphine Clinical Trial. Prison Journal. 93(4):390-410
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE (2013). Individual Patient and Program Factors Related to Prison and Community Treatment Completion in Prison-Initiated Methadone Maintenance Treatment. . Journal of Offender Rehabilitation. 52(8):509-528.
Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PDNunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O’Brien CP (2012). A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Substance Abuse. 33 (1), 48-59. [PMCID: PMC3365863]
Friedmann PD, Hoskinson R, Gordon MS, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O’Connell DJ, Knudsen HK, Shafer MS, Hall E, Frisman LK (2012). Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Substance Abuse. 33 (1), 9-18. [PMCID: PMC3295578]
Gordon MS, Kinlock TW, Couvillion K, Schwartz RP, O’Grady KE (2012). A randomized clinical trial of methadone maintenance for prisoners: Prediction of treatment entry and completion in prison. Journal of Offender Rehabilitation. 51 (4), 222-238
Gryczynski J, Kinlock TW, Kelly SM, O’Grady KE, Gordon MS, Schwartz RP (2012). Opioid agonist maintenance for probationers: Patient-level predictors of treatment retention, drug use, and crime. Substance Abuse. 33 (1), 30-39
Wilson ME, Kinlock TW, Gordon MS, O’Grady KE, Schwartz RP (2012). Post-prison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners. The American Journal on Addictions. 21 (5), 476-487
Wilson ME, Kinlock TW, Gordon MS, O’Grady KE, Schwartz RP (2012). Post-prison HIV-risk behaviors in a randomized clinical trial of methadone maintenance treatment. American Journal on Addictions. 21, 476-487. PMCID: PMC3422766. doi: 10.1111/j.1521-0391.2012.00250.x. PMID: 22882399. PMCID: PMC3422766
Gordon MS, Kinlock TW, Miller PM (2011). Medication-assisted treatment research with criminal justice populations: challenges of implementation. Behavioral Sciences and the Law. 29 (6), 829-845. [PMCID: PMC3243915]
Kinlock TW, Gordon MS, Schwartz RP (2011). Incarcerated populations. In P. Ruiz & E. Strain (Eds.). Lowinson & Ruiz’s Substance Abuse: A Comprehensive Textbook. (Fifth ed., pp. 881-891). Philadelphia, PA: Lippincott Williams & Wilkins
Schwartz RP, Mitchell SG, Gordon MS, and Kinlock TW (2011). Pharmocotherapy. In C. Leukefeld, J. Gregrich & T. P. Gullotta (Eds.), . Handbook on Evidence-Based Substance Abuse Treatment Practice in Criminal Justice Settings, Issues in Childrens’ and Families’ Lives 11.  (pp. 259-277). New York: Springer Publishing.
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT (2010). Developing and implementing a new prison-based buprenorphine treatment program. Journal of Offender Rehabilitation. 49 (2), 91-109. [PMCID: PMC2868193]
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE (2009). Methadone maintenance for prisoners: Results at twelve-months post-release. . Journal of Substance Abuse Treatment. 37, 277-285.
Schwartz RP, Jaffe JH, O’Grady KE, Kinlock TW, Gordon MS, Kelly SM, Wilson ME, Ahmed A (2009). Interim Methadone Treatment: Impact on Arrests..  Drug and Alcohol Dependence. 103, 148-154. doi: 10.1016/j.drugalcdep.2009.03.007. Epub 2009 May 14. PMID: 19443133
Taxman FS and Gordon J (2009). Do fairness and equity matter? An examination of organizational justice among correctional officers in adult prisons. Criminal Justice and Behavior. 36, 695-711
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE (2008). A randomized clinical trial of methadone maintenance for prisoners: Findings at 6-months post-release. Addiction. 103 (8), 1333-1342
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE (2008). A study of methadone maintenance for male prisoners: Three-month post-release outcomes. Criminal Justice and Behavior. 35 (1), 34-47
Garcia CA, Caraballo Correa G, Hernandez Viver AD, Kinlock TW, Gordon MS, Antron Avila C, Colón Reyes I, Schwartz RP (2007). Buprenorphine-Naloxone Treatment for Pre-release Opioid Dependent Inmates in Puerto Rico. Journal of Addiction Medicine. 1(6), 126-132. doi: 10.1097/ADM.0b013e31814b8880. PMID: 21768947
Garcia CA, Correa GC, Hernandez Viver AD, Kinlock TW, Gordon MS, Avila CA, Reyes CI, Schwartz RP (2007). Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. Journal on Addiction Medicine. 1(3), 126-132. doi: 10.1097/ADM.0b013e31814b8880. PMID: 21768947
Gordon MS (2007). Journal of Professional Issues in Criminal Justice. The Examination of Correctional Officers' Organizational Commitment. 2(2), 191-206
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE, Fitzgerald T, Wilson M (2007). A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug and Alcohol Dependence. 91(2-3), 220-227. Epub 2007 Jul 12. PMID: 17628351PMCID: PMC2423344
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE, Fitzgerald T, Wilson M (2007). Examining the Effectiveness of Opioid Agonist Programs for Prisoners at One Month Following Release from Incarceration. Drug and Alcohol Dependence. 91 (2-3), 220-227
Gordon MS (2006). Correctional officer control ideology: Implications for understanding a system. Criminal Justice Studies. 19(3), 225-239
Kinlock TW, and Gordon MS (2006). Substance abuse treatment: New research. In LA Bennett (Ed.), New Topics in Substance Abuse Treatment. Hauppauge, NY: Nova Science Publishers, Inc
Kinlock TW, Schwartz RP, and Gordon MS (2005). The significance of interagency collaboration in developing opioid agonist programs for prisoner. Corrections Compendium. 30(3), 6-30
Kinlock TW, Schwartz RP, and Gordon MS (2005). The significance of interagency collaboration in developing opioid agonist programs for prisoners. Corrections Compendium. 30(3), 28-30
Battjes RJ, Gordon MS, O’Grady KE, and Kinlock TW (2004). Predicting retention of adolescents in substance abuse treatment. Addictive Behavior. 29, 1021-1027
Battjes RJ, Gordon MS, O’Grady KE, Kinlock TW, Katz EC, and Sears EA (2004). Evaluation of a group-based substance abuse treatment program for adolescents. Journal of Substance Abuse Treatment. 27(2), 123-134
Gordon MS, Kinlock TW, and Battjes RJ (2004). Correlates of early substance use and crime among adolescents entering outpatient substance abuse treatment. American Journal of Drug and Alcohol Abuse. 30(1), 21-38
Kinlock TW, Battjes RJ, and Gordon MS (2004). Factors associated with criminal severity among adolescents entering substance abuse treatment. Journal of Drug Issues. 34, 293-318
Kinlock TW, Gordon MS, and Battjes RJ (2004). A Descriptive examination of the pretreatment illegal activities of a nationwide sample of adolescent substance abuse clients. Journal of Psychoactive Drugs. 36, 1-21
Battjes RJ, Gordon MS, O’Grady KE, Kinlock TW, and Carswell MA (2003). Factors that predict adolescent motivation for substance abuse treatment. Journal of Substance Abuse Treatment. 24(3), 221-232
Battjes RJ, Sears EA, Katz EC, Kinlock TW and Gordon MS (2003). Evaluation of a group-based outpatient adolescent substance abuse treatment program. In SJ Stevens & AR Morral (Eds.), Adolescent substance abuse in the United States: Exemplary models from a national evaluation study. Binghamton, NY: Hawthorn Press
Jengeleski JL, and Gordon MS (2003). The Kintock Group, Inc. – Employment Resource Center: A two-year post-release evaluation study. Journal of Correctional Education. 54(1), 27-30
Kinlock T, and Gordon MS (2002). Differential case management. In D Levinson (Ed.), Encyclopedia of crime and punishment. Thousand Oaks, CA: Sage
Jengeleski JL, and Gordon MS (1999). The Kintock Group, Inc. – Employment Resource Center: An assessment of post release outcomes. The Journal of Correctional Education. 50(1), 22-26
Heckert WJ, Jengeleski JL and Gordon MS (1998). Measuring correctional employees’ ideology. Pennsylvania Association on Probation, Parole & Correction Journal. 58(2), 21-26